| Project/Area Number |
22700929
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | 公益財団法人がん研究会 (2011)
Japanese Foundation For Cancer Research (2010) |
|---|
Principal Investigator |
DAN Shingo 公益財団法人がん研究会, がん化学療法センター分子薬理部, 主任研究員 (70332202)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 分子標的治療 / 癌 / 抗がん剤 / PI3K / データベース / バイオマーカー |
|---|
| Research Abstract |
To explore diagnostic biomarkers for predicting the efficacy of PI3K inhibitors including ZSTK474 that we developed previously, we examined the pathway activation status and the efficacy of PI3K inhibitors in a panel of 39 human cancer cell lines(JFCR39), and constructed an integrated database(DB). Using this DB, we found phospho-Akt and KRAS/BRAF mutation prominently correlated with the efficacy and the inefficacy of PI3K inhibitors, respectively. These correlations were confirmed in human tumor xenografts in vivo, suggesting that they could serve as predictive biomarkers in future clinical trials.
|
